Cure My Disease

Don't miss your cure!

 Log in / Sign up

Alcohol injection into adrenal tumors may offer surgery-free blood pressure control

NCT ID NCT07700472

Disease control Sponsor: Chongqing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests a procedure that uses a thin needle guided by an endoscope to inject alcohol into a benign adrenal tumor that produces too much aldosterone, a hormone that raises blood pressure. The goal is to destroy the tumor without surgery. The trial enrolls 30 adults with left-sided aldosterone-producing adenomas who cannot or choose not to have surgery. Participants are followed for safety, tumor disappearance on scans, and biochemical and blood pressure improvements.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
endoscopic ultrasound-guided ethanol ablation
What this could lead to
If successful, this could offer a less invasive alternative to surgery for people with aldosterone-producing adenomas, potentially controlling high blood pressure and reducing medication needs.
What could go wrong
This is a small, early-stage study with only 30 participants, so results may not apply broadly. The procedure carries risks like bleeding, organ damage, or hypertensive emergencies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of left-sided aldosterone-producing adrenal adenoma. 2. Unwillingness to undergo adrenalectomy or presence of contraindications to surgery. 3. Ability and willingness to provide written informed consent. Exclusion Criteria: 1. History of alcohol allergy. 2. Inability to discontinue beta-blockers. 3. Inability to discontinue anticoagulants, antiplatelet agents, or glucocorticoids. 4. Platelet count \<50 × 10\^9/L or uncorrectable coagulation dysfunction. 5. Imaging findings suggestive of adrenal cyst, adrenal hematoma, or myelolipoma. 6. Presence of other active malignancies. 7. Pregnancy or breastfeeding; alcohol abuse; drug abuse; or mental disorder that may interfere with study participation. 8. Severe comorbid conditions, including any of the following: New York Heart Association (NYHA) class III-IV heart failure or hospitalization for worsening chronic heart failure within the previous 3 months; stroke or acute coronary syndrome within the previous 3 months; severe anemia (hemoglobin \<60 g/L); severe hepatic disease (alanine aminotransferase ≥3 × the upper limit of normal); severe renal disease requiring dialysis or estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m²; systemic inflammatory response syndrome (SIRS); poorly controlled diabetes mellitus (fasting blood glucose ≥13.3 mmol/L); severe obesity (body mass index ≥35 kg/m²); untreated aneurysm; or any other severe medical condition that may interfere with treatment or study follow-up. 9. Poor compliance or any other condition that, in the investigator's judgment, would make the participant unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aldosterone-producing adenoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal cortex adenoma aldosterone-producing adrenal cortex adenoma hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aldosterone-producing adenoma Primary aldosteronism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Choongqing, 400016, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.